Rani Therapeutics says oral RT-114 obesity drug candidate tops matched injection exposure in Phase 1a data

• Rani Therapeutics reported positive initial Phase 1a data for RT-114, an oral RaniPill capsule delivering PG-102 for obesity.
• Oral RT-114 produced systemic exposure above 150% versus a matched 12 mg subcutaneous PG-102 dose in healthy volunteers.
• No serious adverse events reported; no adverse events attributed to the capsule; treatment-related events were mild, consistent with GLP-1 class.
• Phase 1a expanded with 15 volunteers receiving two 12 mg oral doses to refine oral-to-subcutaneous pharmacokinetics ahead of Phase 1b.
• Phase 1b repeat-dose study in patients with obesity expected to start in 2026; data anticipated in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rani Therapeutics Holdings Inc. published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.